Birgitta Versluijs

151 Outcome predictors in Allo-LS in children TABLE S3. Univariate predictor analyses for Allo-LS free survival, IPS (N=30) Variable HR (95% CI), P value Age at Allo-LS 1.05 (0.98-1.13), p=0.19 Female 0.5 (0.2-1.31), p=0.16 Primary disease  Malignant  Bone marrow failure syndrome  Inborn error of metabolism  Primary Immune deficiency 1 1.02 (0.29-3.52), p=0.98 1.30 (0.25-6.86), p=0.76 0.71 (0.22-2.29), p=0.57 Stem cell source  Bone marrow  Cord blood 1 1.08 (0.42-2.76), p=0.87 Unrelated donor 2.05 (0.47-8.88), p=0.34 Conditioning regimen  Myeloablative Busulfan based  Myeloablative total body irridiation (TBI) based  Non-myeloablative/reduced intensity conditioning (RIC)  1 0.61 (0.14-2.67), p=0.51 0.32 (0.03-3.59), p=0.35 Human Leukocyte Antigen (HLA) mismatched* 1.79 (0.70-4.61), p=0.23 Hematopoietic cell transplantation (HCT) before 2008 0.54 (0.21-1.35), p=0.19 Respiratory viruses from broncho-alveolar lavage pre-HCT (n=20) 0.69 (0.19-2.45), p=0.56 Respiratory viruses from nasopharyngeal aspirate pre-HCT (n=29) 0.49 (0.18-1.29), p=0.15 Viral reactivation prior to Allo-LS 2.66 (1.15-7.8), p=0.03 Time from HCT to Allo-LS 0.99 (0.98-1.01), p=0.62 Time from symptoms to treatment Allo-LS 1.06 (1.00-1.13), p=0.05 Graft versus Host Disease prior to Allo-LS 4.46 (1.43-13.90), p=0.01 Oxygen therapy 1.78 (0.23-13.40), p=0.58 Intensive care for mechanical ventilation 4.40 (1.43-13.60), p=0.01 High resolution CT composite score (n=21) 1.05 (0.99-1.11), p=0.12 High resolution CT allo score (n=21) 1.00 (0.88-1.14), p=0.97 Respiratory viruses from NPA or BAL at diagnosis Allo-LS (n=28) 0.17 (0.05-0.53), p=0.002 * All 10/10 bone marrow/peripheral blood stem cell products and 6/6 cord blood units were considered matched. Allo-LS, Alloimmune mediated lung syndrome. 8